Browsing Department of Pharmaceutical Engineering by Subject "8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one; abiraterone acetate; alpelisib; androgen receptor; anthracycline derivative; antibody drug conjugate; antineoplastic antimetabolite; apitolisib; asparaginase macrogol; atezolizumab; avelumab; azacitidine; bendamustine; bevacizumab; bicalutamide; bimiralisib; binimetinib; buparlisib; capecitabine; capivasertib; carbon nanotube; carboplatin; cetuximab; cisplatin; citral; cobimetinib; curcumin; cyclophosphamide; cytarabine; cytotoxic T lymphocyte antigen 4; dasatinib; daunorubicin; decitabine; dendrimer; diallyl disulfide; docetaxel; doxorubicin; durvalumab; edelfosine; enzalutamide; epidermal growth factor receptor; epirubicin; eribulin; erlotinib; etoposide; everolimus; floxuridine; fluoropyrimidine derivative; fluorouracil; galunisertib; gambogic acid; gamma secretase inhibitor; gedatolisib; gefitinib; gemcitabine; halofuginone; honokiol; idarubicin; immune checkpoint inhibitor; ipatasertib; irinotecan; ixabepilone; lapachol; liposome; lycopene; metal nanoparticle; methotrexate; mitomycin; mitoxantrone; mk 0752; n (6,7 dihydro 6 oxo 5h dibenz[b,d]azepin 7 yl) 2,2 dimethyl n' (2,2,3,3,3 pentafluoropropyl)propanediamide; nanocarrier; nanoparticle; niclosamide; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase 1; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; niraparib; nirogacestat; olaparib; olinvacimab; omega 3 fatty acid; orteronel; paclitaxel; palbociclib; panitumumab; panobinostat; pembrolizumab; piperine; platinum complex; polymeric micelle; prednisone; programmed death 1 ligand 1; protein tyrosine kinase; quercetin; resveratrol; ridaforolimus; rucaparib; sacituzumab govitecan; saracatinib; selumetinib; silver nanoparticle; sirolimus; small interfering RNA; solid lipid nanoparticle; somatomedin C receptor; talazoparib; taselisib; taxane derivative; teniposide; tetrahydrolipstatin; thymoquinone; unclassified drug; valrubicin; vandetanib; veliparib; vincristine; vinorelbine tartrate; vistusertib; vorinostat"

Browsing Department of Pharmaceutical Engineering by Subject "8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one; abiraterone acetate; alpelisib; androgen receptor; anthracycline derivative; antibody drug conjugate; antineoplastic antimetabolite; apitolisib; asparaginase macrogol; atezolizumab; avelumab; azacitidine; bendamustine; bevacizumab; bicalutamide; bimiralisib; binimetinib; buparlisib; capecitabine; capivasertib; carbon nanotube; carboplatin; cetuximab; cisplatin; citral; cobimetinib; curcumin; cyclophosphamide; cytarabine; cytotoxic T lymphocyte antigen 4; dasatinib; daunorubicin; decitabine; dendrimer; diallyl disulfide; docetaxel; doxorubicin; durvalumab; edelfosine; enzalutamide; epidermal growth factor receptor; epirubicin; eribulin; erlotinib; etoposide; everolimus; floxuridine; fluoropyrimidine derivative; fluorouracil; galunisertib; gambogic acid; gamma secretase inhibitor; gedatolisib; gefitinib; gemcitabine; halofuginone; honokiol; idarubicin; immune checkpoint inhibitor; ipatasertib; irinotecan; ixabepilone; lapachol; liposome; lycopene; metal nanoparticle; methotrexate; mitomycin; mitoxantrone; mk 0752; n (6,7 dihydro 6 oxo 5h dibenz[b,d]azepin 7 yl) 2,2 dimethyl n' (2,2,3,3,3 pentafluoropropyl)propanediamide; nanocarrier; nanoparticle; niclosamide; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase 1; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; niraparib; nirogacestat; olaparib; olinvacimab; omega 3 fatty acid; orteronel; paclitaxel; palbociclib; panitumumab; panobinostat; pembrolizumab; piperine; platinum complex; polymeric micelle; prednisone; programmed death 1 ligand 1; protein tyrosine kinase; quercetin; resveratrol; ridaforolimus; rucaparib; sacituzumab govitecan; saracatinib; selumetinib; silver nanoparticle; sirolimus; small interfering RNA; solid lipid nanoparticle; somatomedin C receptor; talazoparib; taselisib; taxane derivative; teniposide; tetrahydrolipstatin; thymoquinone; unclassified drug; valrubicin; vandetanib; veliparib; vincristine; vinorelbine tartrate; vistusertib; vorinostat"

Sort by: Order: Results:

  • Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC) 
    Chaudhuri, Aiswarya; Kumar, Dulla Naveen; Dehari, Deepa; Singh, Sanjay; Kumar, Pradeep; Bolla, Pradeep Kumar; Kumar, Dinesh; Agrawal, Ashish Kumar (MDPI, 2022-05)
    Triplenegative breast cancer (TNBC) is considered one of the unmanageable types of breast cancer, involving devoid of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER 2) receptors. Due to their ...

Search in IDR


Advanced Search

Browse

My Account